Accelerate oligonucleotide and peptide products from early discovery to late-stage development & commercialization.

REPORT: State of Oligo, Peptide, mRNA and CRISPR Therapeutics 2019

ArticleImage

Download exclusive research

In June 2019 Informa Connect Life Sciences conducted a survey of oligonucleotide, peptide, CRISPR and mRNA therapeutics professionals from around the world. Based on 124 responses, this report gives an overview of how insiders really view the state of the industry, revealing unique insights into potential opportunities and challenges around drug development, manufacture, delivery, technologies, regulations and collaborations. Dan Stanton, editor of BioProcess Insider, introduces the report, exploring what some of the key takeaways mean for the industry.

To download simply log in or register for an Informa Connect account, which will give you access to all our exclusive premium content. Have any questions or interested in sponsoring future content? Email andrew.burrows@informa.com.

Oligo, Peptide, mRNA and CRISPR Therapeutics Report

Log in or create an Informa Connect account to access this content

Creating an account also means you'll get special access to article updates and exclusive industry content.